This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
PneumRx inflates its coffers with $11.9mm Series C round; up to $33mm
PneumRx Inc. (device to treat emphysema) has raised $11.9mm through its Series C round. Since the company filed its initial Form D, which stated it may bring in another $8.6mm before closing the financing, PneumRx has indicated it has up to $33mm in capital commitments. The oversubscribed round was co-led by Forbion Capital Partners, Endeavour Vision, and a strategic corporate partner. Current backers Adams Street Partners, Telegraph Hill Partners, Alta Partners, Spray Venture Partners, Silicon Valley Bank, and Leader Ventures also participated. PneumRx will use the proceeds to advance European sales of the RePneu lung volume reduction coil and to perform a pivotal US trial to support a PMA application. Concurrent with the financing, representatives from Forbion and Endeavour joined PneumRx’s board.
Surgical Equipment & Devices
Minimally or Less Invasive
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?